ONLINE SUPPLEMENT

Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: Implications for trials of renal denervation

Hitesh C Patel,1,2,* Carl Hayward,1,2,* Baris Ata Ozdemir,3 Stuart D Rosen,2,4 Henry Krum,5 Alexander R Lyon,1,2 Darrel P Francis,2 Carlo di Mario1,2

1 NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK

2 National Heart and Lung Institute, Imperial College, London, UK

3 Department of Outcomes Research, St. George’s Vascular Institute, St George’s University, London, UK

4 Department of Cardiology, Ealing Hospital NHS Trust, Southall, London, UK

5 Monash Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, VIC, Australia

*HP and CH contributed equally to the manuscript

Corresponding Author:

Dr Hitesh Patel, Cardiology Research Fellow

Cardiovascular BRU, Royal Brompton Hospital

London UK, SW3 6NP

Tel: +44 207 352 8121 x2920

Fax: +44 207 351 8184

Email:


S1: Flow chart for study selection. BP= blood pressure

S2: Individual characteristics of the 52 non-resistant hypertension and 8 resistant hypertension trials included in the meta-analysis. SBP=systolic blood pressure; DBP=diastolic blood pressure; ABPM=ambulatory blood pressure monitoring; NR=no record.


Supplementary references

S1. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe D. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res. 2006;29:997-1005.

S2. Jordan J, Engeli S, Boye S, Le Breton S, Keefe D. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension. 2007;49:1047-1055.

S3. Gradman A, Schmieder R, Lins R, Nussberger J, Chiang Y, Bedigian M. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012-1018.

S4. Geiger H, Barranco E, Gorostidi M, Taylor A, Zhang X, Xiang Z, Zhang J. Combination therapy with various combination of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J Clin Hypertens. 2009;11:324–332.

S5. Puig J, Schunkert H, Taylor A, Boye S, Jin J, Keefe D. Evaluation of the dose-response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension. Clin Ther. 2009;31:2839–2850.

S6. Oh BH, Mitchell J, Herron J, Chung J, Khan M, Keefe D. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157-1163.

S7. Pool J, Schmieder R, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. AJH. 2007;20:11-20.

S8. Drummond W, Munger M, Essop M, Maboudian M, Khan M, Keefe D. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens. 2007;9:742-750.

S9. Drummond W, Sirenko Y, Ramos E, Baek I, Keefe D. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination. A placebo-controlled study. Am J Cardiovasc Drugs. 2011;11:327-333.

S10. Villa G, Le Breton S, Ibram G, Keefe D. Efficacy, safety, and tolerability of aliskiren monotherapy administered with a light meal in elderly hypertensive patients: a randomized, double-blind, placebo-controlled, dose-response evaluation study. J Clin Pharmacol. 2012;52:1901-1911.

S11. Villamill A, Chrysant S, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217-226.

S12. Littlejohn T, Jones S, Zhang J, Hsu H, Keefe D. Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study. J Hum Hypertens. 2013;27:321-327.

S13. Schmieder R, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J, van Ingen H. Circulation. 2009;119:417-425.

S14. Blumenstein M, Romaszkp J, Calderon A, Andersen K, Ibram G, Liu Z, Zhang J. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25mg alone. Curr Med Res Opin. 2009; 25:903-910.

S15. Glorioso N, Thomas M, Troffa C, Argiolas G, Patel S, Baek I, Zhang J. Antihypertensive efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients with an inadequate response to aliskiren monotherapy. Current Vascular Pharmacology. 2012;10:748-755.

S16. Pfeiffer D, Rennie N, Papst C, Zhang J. Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy. Current Vascular Pharmacology. 2012;10:773-780.

S17. Nickenig G, Simanenkov V, Lembo G, Rodriguez P, Salko T, Ritter S, Zhang J. Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders. Blood Pressure. 2008;17:31-40.

S18. Oparil S, Yarows S, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised double-blind trial. Lancet. 2007;370:221-29.

S19. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200796Orig1s000MedR.pdf (11 September 2014).

S20. Bakris G, Sica D, Weber M, White W, Roberts A, Perez A, Cao C, Kupfer S. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens. 2011;13:81-88.

S21. White W, Weber M, Sica D, Bakris G, Perez A, Cao C, Kupfer S. Effects of angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57:413-420.

S22. Saruta T, Kageyama S, Ogihara T, Hiwada K, Ogawa M, Tawara K, Gatlin M, Garthwaite S, Bittman R, Patrick J. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study. J Clin Hypertens. 2004;6:175-185.

S23. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-437_Inspra_Medr_P3.pdf (11 September 2014).

S24. Weinberger M, Roniker B, Krause S, Weiss R. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. AJH. 2002;15:709-716.

S25. Calhoun D, White W, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz M, Menard J. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011;124:1945-1955.

S26. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, Fakouhi K. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40:117-123.

S27. White W, Carr A, Krause S, Jordan R, Roniker B, Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol. 2003;92:38-42.

S28. Flack J, Oparil S, Pratt H, Roniker B, Garthwaite S, Kleiman J, Yang Y, Krause S, Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003;41:1148-55.

S29. Chan T, Woo K, Nicholls M. The application of nebivolol in essential hypertension: a double-blind, randomized, placebo-controlled study. Int J Cardiol. 1992;35:387-395.

S30. Saunders E, Smith W, DeSalvo K, Sullivan W. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens. 2007;9:866-875.

S31. Greathouse M. Nebivolol efficacy and safety in patients with stage I-II hypertension. Clin Cardiol. 2010;33:E20–E27.

S32. Weiss R, Weber M, Carr A, Sullivan W. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel B-blocker, in patients with mild to moderate hypertension. J Clin Hypertens. 2007;9:667-676.

S33. Weber M, Basile J, Stapff M, Khan B, Zhou D. Blood pressure effects of combined B-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril. J Clin Hypertens. 2012;14:588–592.

S34. Deedwania P, Shea J, Chen W, Brener L. Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes. J Clin Hypertens. 2013;15:270-278.

S35. Van Nueten L, Taylor F, Robertson J. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1998;12:135-140.

S36. Punzi H, Lewin A, Lukic T, Goodin T, Chen W. Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial. Ther Adv Cardiovasc Dis. 2010 4: 349-357.

S37. Lewin A, Punzi H, Xiaohui L, Stapff M. Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized-placebo-controlled trial. Clin Ther. 2013;35:142–152.

S38. Neutel H, Smith D, Gradman A. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension. J Hum Hypertens. 2010;24:64-73.

S39. Giles T, Khan B, Lato J, Brener L, Ma Y, Lukic T. Nebivolol monotherapy in young adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial. J Clin Hypertens. 2013;15:687-693.

S40. Weiss R, Stapff M, Lin Y. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial. Am J Cardiovasc Drugs. 2013;13:129-140.

S41. Giles T, Weber M, Basile J, Gradman A, Bharucha D, Chen W, Pattathil M, for the NAC-MD-01 Study Investigators. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet. 2014;383:1889-98.

S42. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-286_Benicar_medr_P2.pdf (11 September 2014).

S43. Chrysant S, Weber M, Wang A, Hinman D. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17:252-259.

S44. Giles T, Oparil S, Silfani T, Wang A, Walker F, on behalf of the study investigators. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens. 2007;9:187–195.

S45. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-286_Benicar_medr_P3.pdf (11 2014).

S46. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-286_Benicar_medr_P5.pdf (11 2014).

S47. Chrysant S, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587-604.

S48. Volpe M, Brommer P, Haag U, Miele C. Effiacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy. A randomized, double-blind, parallel-group, multicentre study. Clin Drug Invest. 2009;29:11-25.

S49. Witham M, Ireland S, Houston G, Gandy S, Waugh S, MacDonald T, Mackenzie I, Struthers A. Vitamin D therapy to reduce blood pressure and left ventricular hypertrophy in resistant hypertension: randomized, controlled trial. Hypertens. 2014;63:706-712.

S50. Black H, Bakris G, Weber M, Weiss R, El Shahawy M, Marple R, Tannoury , Linas S, Wiens B, Linseman J, Roden R, Gerber M. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens. 2007;9:760-769.

S51. Vaclacik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, Vaclavik T, Husar R, Kocianova E, Taborsky M. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069-1075.

S52. Oxlund C, Henriksen J, Tarnow L, Schousboe K, Gram J, Jacobsen I. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31:2094-2102.

S53. Bakris G, Lindholm L, Black H, Krum H, Linas S, Linseman J, Arterburn S, Sager P, Weber M. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824-830.

S54. Weber M, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman J, Wiens B, Warren M, Lindholm L. A selective endothelin-receptor anatagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374-1423-31.

2